Lyell Immunopharma, Inc. Peo Actually Paid Comp Amt
Lyell Immunopharma, Inc. (LYEL) reported Peo Actually Paid Comp Amt of $9.64 million for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-24.
Financial Statements › Cash Flow › Other Cash Flow Items
ecd:PeoActuallyPaidCompAmt · last filed 2026-04-24
| Period end | Peo Actually Paid Comp Amt 12 month |
|---|---|
| 2025-12-31 | $9.64M DEF 14A · filed 2026-04-24 |
| 2024-12-31 | -$3.24M DEF 14A · filed 2026-04-24 |
| 2023-12-31 | -$7.94M DEF 14A · filed 2026-04-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |